Cardiology Business

The State of the TAVR Market in 2025

2025 has been a year of many cardiology trends, with one stand out technology capturing much of the spotlight – transcatheter aortic valves. To keep our valves in a row, Cardiac Wire has compiled a breakdown of the top TAVR makers, movers, shakers, and potential future players. 

Starting off with the biggest player, Edwards Lifesciences controls about 60-70% of the U.S. TAVR market and has some of the most proven tech in the segment…

  • Edwards markets the balloon-expandable SAPIEN platform, which is the longest‑established TAVR system (FDA-approved since 2011).
  • Earlier this year, the FDA approved SAPIEN’s use for lower-risk and asymptomatic patients thanks to positive results from the EARLY TAVR trial.
  • Shoring up its TAVR pipeline for AR therapy, Edwards also acquired JenaValve and JC Medical in 2024 (although the FTC is now trying to block JenaValve).

Medtronic isn’t far behind and essentially makes up the remainder of the market, with 30-35% of TAVR procedures worldwide using a Medtronic valve.

  • The company’s product line includes the CoreValve / Evolut series (self‑expanding nitinol valves).
  • Some studies, like SMART, suggest Medtronic’s valves could lead to better outcomes in patients with smaller aortic annuli.

Abbott doesn’t intend to let TAVR stay a two horse race for long, and is working on gaining regulatory approval for its own devices.

  • Abbott currently produces the Navitor TAVR system (successor to its older Portico), which is in active clinical trials including the ENVISION pivotal study.

Boston Scientific was a TAVR player up until earlier this year when it quietly discontinued its Acurate product line due to unfavorable trial results and potential stroke risks.

So who is left to challenge Edwards and Medtronic for the TAVR throne? 

  • Anteris Technologies – Anteris’ balloon-expandable DurAVR THV system looks and works like a human valve (all other TAVRs have three fixed leaflets), and claims calcification benefits.
  • JenaValve Technology – Originally Chinese but facing acquisition from Edwards, the JenaValve Trilogy system is undergoing FDA trials for aortic regurgitation and might allow more complex aortic access methods.
  • JC Medical – Now also owned by Edwards outside of China, the J‑Valve system is used for both AS/regurgitation and has multiple trials underway.
  • Meril Life Sciences – Developer of the Myval TAVR system, India’s first homegrown THV, which launched commercially in India and was CE‑marked in 2019.

The Takeaway

TAVR is certainly here to stay, and while it’s been dominated by two companies for most of its short history, the competition could just be getting started.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology August 28, 2025

Cardiologists, Practice What You Preach! August 28, 2025

Cardiologists might be struggling with the same lifestyle challenges they counsel patients about, as a national survey of ACC members revealed significant gaps between what physicians’ recommend and how they act. The ACC CardioSurve study surveyed 166 U.S. cardiologists about their training in lifestyle medicine and clinical recommendations across all six lifestyle pillars, revealing some […]

Obesity Care August 25, 2025

GLP-1s Work, But Not for Free August 25, 2025

Real-world semaglutide (Wegovy) patients might be experiencing a healthcare cost paradox, after a recent analysis in JAMA showed that GLP-1s successfully reduce weight and improve cardiovascular risk factors, but lead to increased patient healthcare expenditures in the short term. The real-world analysis examined 23.5k adults prescribed semaglutide between January 2018 and January 2025 across two […]

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Like the website? You'll love the newsletter

Completely free. Every Monday and Thursday.

CW Phone Square

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!